Radical radiotherapy for non-melanoma skin cancer: orthovoltage vs. electronic brachytherapy
PO-1436
Abstract
Radical radiotherapy for non-melanoma skin cancer: orthovoltage vs. electronic brachytherapy
Authors: María Cerrolaza1, Pilar Sanagustin1, Victoria Navarro1, Cecilia Escuin1, Alberto Lanuza1, Sonia Flamarique1, Arantxa Campos1, Manuela Lanzuela1, Reyes Ibañez1, Martin Tejedor1
1University Hospital Miguel Servet, Radiotherapy, ZARAGOZA, Spain
Show Affiliations
Hide Affiliations
Purpose or Objective
Non melanoma skin cancer is the most
frequent malignancy worldwide. Its development is related to age, high exposure
to ultraviolet rays, fair skin and immunosuppression. Eighty percent usually
occur in areas of the head and neck and are mostly basal cell carcinomas and
squamous cell carcinomas.
Surgery is usually the treatment of choice,
however, radiotherapy is an effective option in patients who are not candidates
for surgical resection due to comorbidities, age, location or post-surgical
morbidity.
Our aim has been to evaluate the
differences in effectiveness and toxicity between two types of superficial
radiotherapy treatments: low energy photons and electronic brachytherapy.
Material and Methods
Patients with non-melanoma skin cancer
treated with superficial radiotherapy with radical intent between October 2019
and June 2021 were retrospectively collected. Treatment was administered by
low-energy photons using Therapax 150 orthovoltage devices or 50 Kv X-rays
using the Axxent Xoft device (electronic surface brachytherapy). Demographic and anatomopathologic data, as
well as treatment characteristics, toxicities (CTCAE V5) and observed results
were compared between both groups. Student's T was used for quantitative variables
and chi-square for qualitative variables with p<0.05 being considered as
statistically significant differences.
Results
There were 61 treatments 51% performed with
Axxent and 49% with Therapax.
No statistically significant differences
were found between Axxent and Therapax in terms of sex distribution (men 57%
and 52% respectively), mean age (84.3 and 85.3 years), type of histology basal
cell (77% and 80%), squamous (13% and 20%) and lymphoma (5% and 0%). No
differences were also found in terms of their main locations: nasal (32% and 37%),
fronto-parietal (29% and 27%) and malar (13% and 10%).
Differences were found between the total
mean dose in both groups (p= 0.00) 41.06 Gy Axxent and 50.67 Gy Therapax as
well as the equivalent biological dose 52.06 Gy and 67.03 Gy respectively (p=
0.00).
No differences were found in the degree of
toxicity observed between Axxent and Therapax presenting radiodermatitis at the
end of treatment G2 in 16% and 20% (P= 0.69) and G3 in 16% and 3% respectively
(p=0.09). No correlation was found either between BED or EQD2 with respect to
the degree of toxicity.
Regarding the observed clinical
pathological response, no differences were found (P=0.83) between treatments
with a percentage of complete response of 74% and 83% respectively.
Conclusion
Both superficial low energy photon
radiotherapy and superficial electron brachytherapy are effective and well
tolerated treatments in non-melanoma skin cancer with radical intent.